Lung Carcinoma Clinical Trials in Barcelona
13 recruitingBarcelona, Spain
Showing 1–13 of 13 trials
Recruiting
Phase 3
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Small Cell Lung Carcinoma
AstraZeneca70 enrolled15 locationsNCT06992609
Recruiting
Phase 1Phase 2
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled22 locationsNCT07407933
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Phase 1
A Study of LY4175408 in Participants With Advanced Cancer
Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.590 enrolled143 locationsNCT06881784
Recruiting
Phase 1
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC110 enrolled48 locationsNCT04938817
Recruiting
Phase 1
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Non-small Cell Lung CancerMetastatic Lung CancerNSCLC+3 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)350 enrolled35 locationsNCT06343402
Recruiting
Phase 2
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Neuroendocrine NeoplasmsSmall Cell Lung CarcinomaExtra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim204 enrolled59 locationsNCT05882058
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting
Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Carcinoma, Non-Small Cell LungGastroesophageal Junction AdenocarcinomaStomach Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Non-Small-Cell Lung Carcinoma
AstraZeneca210 enrolled48 locationsNCT04995523